Willingdon Wealth Management Has Boosted Amgen (AMGN) Position By $682,550; Ricebran Technologies (RIBT) Sentiment Is 1.29

August 12, 2018 - By Catherine Diaz

Amgen Inc. (NASDAQ:AMGN) Logo

Ricebran Technologies (RIBT) investors sentiment decreased to 1.29 in Q1 2018. It’s down -0.31, from 1.6 in 2017Q4. The ratio turned negative, as 9 hedge funds opened new and increased holdings, while 7 cut down and sold their holdings in Ricebran Technologies. The hedge funds in our database now have: 937,360 shares, up from 675,712 shares in 2017Q4. Also, the number of hedge funds holding Ricebran Technologies in top ten holdings was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 5 Increased: 6 New Position: 3.

Willingdon Wealth Management increased Amgen Inc (AMGN) stake by 49.75% reported in 2018Q1 SEC filing. Willingdon Wealth Management acquired 4,015 shares as Amgen Inc (AMGN)’s stock declined 5.44%. The Willingdon Wealth Management holds 12,086 shares with $2.06 million value, up from 8,071 last quarter. Amgen Inc now has $125.84B valuation. The stock increased 0.23% or $0.45 during the last trading session, reaching $194.42. About 1.52 million shares traded. Amgen Inc. (NASDAQ:AMGN) has risen 14.68% since August 12, 2017 and is uptrending. It has outperformed by 2.11% the S&P500. Some Historical AMGN News: 16/05/2018 – Amgen Receives European Commission Approval for Repatha(R) (Evolocumab) to Prevent Heart Attack and Stroke in Adults With Established Cardiovascular Disease; 24/04/2018 – Amgen 1Q Adj EPS $3.47; 11/04/2018 – MYLAN NV – CO, FUJIFILM KYOWA KIRIN BIOLOGICS EXPECT TO RECEIVE DECISION FROM EMA REGARDING MAA FOR PROPOSED BIOSIMILAR TO HUMIRA IN H2 2018; 10/03/2018 – Regeneron/Sanofi offer new Praluent pricing to break reimbursement logjam; 10/03/2018 – Regeneron and Sanofi Announce Plans to Make Praluent┬« (alirocumab) More Accessible and Affordable for Patients with the Greate; 19/05/2018 – Egan Bernal Becomes First Colombian Amgen Tour of California Champion; Countryman Fernando Gaviria Sweeps Sprint Stages at; 17/05/2018 – U.S. FDA approves Amgen migraine drug, price set at $6900/yr; 23/03/2018 – Amgen Receives Positive CHMP Opinion Recognizing That Repatha┬« (evolocumab) Prevents Heart Attacks And Strokes; 18/05/2018 – Novartis, Amgen: FDA Approves Aimovig; 19/05/2018 – Egan Bernal Becomes First Colombian Amgen Tour of California Champion; Countryman Fernando Gaviria Sweeps Sprint Stages at Sacramento Race Conclusion

Perkins Capital Management Inc holds 0.26% of its portfolio in RiceBran Technologies for 180,500 shares. Bard Associates Inc owns 49,275 shares or 0.04% of their US portfolio. Moreover, Acadian Asset Management Llc has 0% invested in the company for 9,889 shares. The North Carolina-based Bank Of America Corp De has invested 0% in the stock. Blackrock Inc., a New York-based fund reported 13,690 shares.

RiceBran Technologies processes and markets healthy, natural, and nutrient dense products derived from raw rice bran. The company has market cap of $65.73 million. The firm makes and distributes stabilized rice bran in various granulations with other products and derivatives. It currently has negative earnings. It also extracts crude rice bran oil and defatted rice bran from rice bran, which are processed into refined rice bran oil, as well as compounded animal nutrition products for horses, cows, swine, sheep, and poultry; and various food and animal nutrition products derivatives and co-products.

The stock increased 1.12% or $0.03 during the last trading session, reaching $2.71. About 350,765 shares traded or 34.65% up from the average. RiceBran Technologies (RIBT) has risen 84.88% since August 12, 2017 and is uptrending. It has outperformed by 72.31% the S&P500. Some Historical RIBT News: 08/05/2018 – RiceBran Technologies Backs 2018 Rev $16M; 15/03/2018 – RICEBRAN TECHNOLOGIES RIBT.O SEES FY 2018 REVENUE $16 MLN; 15/03/2018 RiceBran Technologies Reports Full Year 2017 Financial Results; 24/05/2018 – RiceBran Technologies to Relocate its Corporate Headquarters to the Woodlands in Texas as of May 30, 2018; 15/05/2018 – Fintel Insider Buying Report: RiceBran Technologies (RIBT), Novavax, Inc. (NVAX), And Others; 26/03/2018 – CONTINENTAL GRAIN COMPANY NOW REPORTS 18.9 PCT STAKE IN RICEBRAN TECHNOLOGIES AS OF MARCH 21 VS A STAKE OF 16.2 PCT AS OF SEPT 13, 2017 – SEC FILING; 08/05/2018 – RiceBran Technologies Continues to Believe Balance Sheet Is Sufficient to Support Growth Plan for 2018 and Beyond; 23/04/2018 – DJ RiceBran Technologies, Inst Holders, 1Q 2018 (RIBT); 28/03/2018 – FIRST EAGLE INVESTMENT MANAGEMENT LLC REPORTS 5.35 PCT PASSIVE STAKE IN RICEBRAN TECHNOLOGIES AS OF FEB 23, 2018 – SEC FILING; 16/04/2018 – Global Rice Bran Oil Market 2010-2017 & 2018-2023 – ResearchAndMarkets.com

Since January 1, 0001, it had 9 insider purchases, and 0 sales for $2.34 million activity.

More recent RiceBran Technologies (NASDAQ:RIBT) news were published by: Seekingalpha.com which released: “RiceBran Technologies (RIBT) CEO Dr. Robert Smith on Q2 2018 Results – Earnings Call Transcript” on August 05, 2018. Also Streetinsider.com published the news titled: “RiceBran Technologies (RIBT) Reports In-Line Q2 EPS; Lowers FY18 Revenue Guidance” on August 02, 2018. Benzinga.com‘s news article titled: “RiceBran Technologies to Host Q2 2018 Financial Results Conference Call on August 2nd at 4:30 PM EDT” with publication date: July 27, 2018 was also an interesting one.

Investors sentiment decreased to 0.88 in Q1 2018. Its down 0.34, from 1.22 in 2017Q4. It is negative, as 67 investors sold AMGN shares while 557 reduced holdings. 114 funds opened positions while 435 raised stakes. 502.72 million shares or 8.88% less from 551.71 million shares in 2017Q4 were reported. Baldwin Brothers Incorporated Ma accumulated 65,678 shares. Colony Gru Inc Ltd Liability Corp stated it has 104,440 shares. Moreover, Daiwa Secs Grp Inc has 0.05% invested in Amgen Inc. (NASDAQ:AMGN). New Mexico Educational Retirement Board reported 63,945 shares. Capital Invest Advsrs Ltd Company invested 0.25% in Amgen Inc. (NASDAQ:AMGN). Palladium Partners Ltd Liability holds 1.39% or 110,356 shares in its portfolio. Personal Capital Advsrs invested 0.42% in Amgen Inc. (NASDAQ:AMGN). Tirschwell & Loewy holds 77,024 shares. Clarivest Asset Management Lc reported 392,290 shares. Coe Capital Limited Liability holds 1,905 shares or 0.35% of its portfolio. Scott Selber Incorporated stated it has 1.46% in Amgen Inc. (NASDAQ:AMGN). Dean Inv Assoc Llc accumulated 13,977 shares or 0.35% of the stock. First American Retail Bank reported 0.37% stake. Qs Invsts Ltd Liability Com holds 0.2% in Amgen Inc. (NASDAQ:AMGN) or 112,767 shares. Hl Fincl Serv Ltd Llc holds 45,628 shares or 0.14% of its portfolio.

More important recent Amgen Inc. (NASDAQ:AMGN) news were published by: Fool.com which released: “Better Buy: Gilead Sciences, Inc. vs. Amgen Inc.” on August 08, 2018, also Benzinga.com published article titled: “Nasdaq, Tech Names Might Come Under Pressure Following Facebook’s Weak Results”, 247Wallst.com published: “Why Have Short Sellers Backed Off Major Biotechs?” on August 10, 2018. More interesting news about Amgen Inc. (NASDAQ:AMGN) was released by: Seekingalpha.com and their article: “BeiGene launches late-stage study of tislelizumab in first-line lung cancer” with publication date: August 09, 2018.

Among 7 analysts covering Amgen Inc (NASDAQ:AMGN), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Amgen Inc had 9 analyst reports since March 12, 2018 according to SRatingsIntel. The rating was maintained by JP Morgan on Friday, July 27 with “Neutral”. Morgan Stanley maintained Amgen Inc. (NASDAQ:AMGN) rating on Wednesday, April 25. Morgan Stanley has “Overweight” rating and $200 target. Barclays Capital maintained the stock with “Equal-Weight” rating in Thursday, April 5 report. The stock of Amgen Inc. (NASDAQ:AMGN) has “Neutral” rating given on Monday, July 30 by Robert W. Baird. On Friday, July 27 the stock rating was maintained by PiperJaffray with “Overweight”. The firm has “Buy” rating by Jefferies given on Friday, July 27. The stock of Amgen Inc. (NASDAQ:AMGN) has “Neutral” rating given on Monday, July 30 by Citigroup. Morgan Stanley maintained Amgen Inc. (NASDAQ:AMGN) rating on Friday, July 13. Morgan Stanley has “Overweight” rating and $210 target.

Since February 14, 2018, it had 0 insider purchases, and 5 selling transactions for $1.36 million activity. Another trade for 1,525 shares valued at $289,369 was made by Harper Sean E on Friday, March 16.

Amgen Inc. (NASDAQ:AMGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts